Novel Biologics
Focused on World’s Most Debilitating Diseases
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune  diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways.  Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.

There is a large unmet need for biologic therapies in China, where the majority of the world’s most efficacious drugs are not available or are not affordable. Clover believes the Chinese people deserve access to these modern therapies and is seeking to change this paradigm.